Amarantus BioScience Holdings, Inc. (OTCPK:AMBS) (‘AMBS’) acquired certain assets of Avant Diagnostics, Inc. (OTCPK:AVDX) (‘Avant’) for $0.37 million on March 30, 2018. Under the transaction, AMBS will issue 1 million common shares and assume $0.3225 million of contingent liabilities as consideration to acquire all intellectual property related to MSPrecise, Lympro, and NuroPro assets of Avant. The transaction is subject to execution of lock-up agreement by both the parties. Stephen A. Cohen of Sheppard, Mullin, Richter & Hampton LLP acted as legal advisor to Avant. Amarantus BioScience Holdings, Inc. (OTCPK:AMBS) completed the acquisition of certain assets of Avant Diagnostics, Inc. (OTCPK:AVDX) on March 30, 2018.